Literature DB >> 32072793

Birth of a healthy boy following preimplantation genetic diagnosis for congenital adrenal hyperplasia.

Fakhredin Reihani-Sabet1, Poopak Eftekhari-Yazdi2, Parnaz Borjian Boroujeni1, Javad Roodgar Saffari1, Navid Almadani1, Shirin Boloori1, Mohammad Reza Zamanian1.   

Abstract

Classical 3β-HSD deficiency due to mutations in the HSD3B2 gene is responsible for a rare form of congenital adrenal hyperplasia (CAH) and is identified by varying degrees of salt wasting. Preimplantation genetic diagnosis (PGD) was performed in a couple carrying mutation c.690 G>A in the HSD3B2 gene. Four polymorphic short tandem repeat markers closely linked to the HSD3B2 gene (D1S185, D1S453, D1S514, D1S540) for linkage analysis in conjunction with the direct mutation analysis were used in embryo genotyping. Two CODIS STRs (VWA and THO1) were also used to confirm embryo zygosity and rule out possible contaminations. Finally, SRY and AMYLOGENIN markers were used for embryo sex determination. PGD was performed by fluorescent multiplex seminested polymerase chain reaction and sequencing. Six embryos were tested and one male carrier embryo was transferred, resulting in the birth of a healthy boy.

Entities:  

Keywords:  congenital adrenal hyperplasia (CAH); molecular PGD; monogenic disease; preimplantation genetic diagnosis

Mesh:

Year:  2020        PMID: 32072793      PMCID: PMC7169911          DOI: 10.5935/1518-0557.20190085

Source DB:  PubMed          Journal:  JBRA Assist Reprod        ISSN: 1517-5693


INTRODUCTION

Congenital adrenal hyperplasia (CAH) comprises a group of several autosomal recessive disorders stemmed from the deficiency of one of five enzymes mediating the biochemical steps in steroidogenesis, which include the production of mineralocorticoids, glucocorticoids, or sex steroids from cholesterol by the adrenal glands (Aceto ; Speiser & White, 2003). Males and females are equally at risk for these disorders (Aceto ). In humans, there are two forms of 3 β -hydroxysteroid dehydrogenase enzyme (3β-HSD): type I and type II with 93.5% homology. 3β-HSD enzyme type II (HSD3B2) is responsible for the conversion of Δ5 (delta 5) to Δ4 (delta 4) steroids, and is almost exclusively expressed in the gonads and adrenal cortex. Type I (HSD3B1) is mainly expressed in the mammary gland, placenta, and skin. Both 3β-HSD genes are located on chromosome 1p13. Enzyme HSD3B2 catalyzes the biosynthesis of progesterone, which is the precursor for aldosterone, and 17α-hydroxyprogesterone, the precursor for cortisol in the adrenal cortex and androstenedione, testosterone, and estrogen in the adrenal cortex and gonads (Rheaume ; Simard ). 3β-HSD deficiency is categorized into classical and nonclassical forms (Simard ). Classical 3β-HSD deficiency due to mutations in the HSD3B2 gene is responsible for a rare form of CAH identified by varying degrees of salt wasting (SW). Accordingly, the classical form leads to impaired cortisol synthesis and salt-wasting in its most severe form (Bongiovanni ; Simard ). Preimplantation genetic diagnosis (PGD) has been introduced as an alternative to prenatal diagnosis and termination of pregnancy in couples at high risk of transmitting single gene disorders to their offspring. The goal of PGD is to detect a particular genetic disease on oocytes or embryos obtained through assisted reproductive technologies (ART) before clinical pregnancy is achieved. This is done by selecting and transferring unaffected embryos to the uterus following direct/indirect mutation analysis. In the present case, linkage analysis was performed using polymorphic short tandem repeat (STR) markers closely linked to the mutated HSD3B2 gene to prepare a further proof of genotyping (indirect analysis) through Sanger sequencing (direct detection) and evaluation for possible allele drop out (ADO). Contamination of exogenous DNA was also evaluated with CODIS-STR markers with different (Fiorentino ; Gutiérrez-Mateo ). This case report emphasizes the successful application of PGD for CAH, which resulted in the birth of a healthy boy. To our knowledge, this is the first report of a child born free of CAH after PGD in Iran.

CASE DESCRIPTION

The couple, a 35-year-old woman and a 39-year-old man, was referred to the Royan Institute for genetic counseling. They had had a miscarriage, a dead son to CAH, and a 9-year-old affected girl before coming to our clinic (Fig. 1). Genetic assessment revealed that the couple were heterozygote for the c.690G>A mutation of the HSD3B2 gene and did not manifest the disease. The couple wished to have an unaffected child and underwent ART with PGD. They also expressed the wish to have a baby boy.
Figure 1

Family tree; the couple (probands) carry the c.690G>A mutation in the HSD3B2 gene. The index case suffers from CAH

Family tree; the couple (probands) carry the c.690G>A mutation in the HSD3B2 gene. The index case suffers from CAH

MATERIAL AND METHODS

Controlled ovarian stimulation was performed via the long protocol of down-regulation with a gonadotropin-releasing hormone agonist and recombinant FSH for 12 days. Seven oocytes were retrieved and six cleaving embryos were available for biopsy on day 3. Blastomeres were lysed for 10 min at 65°C in lysis buffer (dTT 50mM, KOH 200mM) and then analyzed using our in-house PCR protocol. Preliminary genetic evaluation (Pre-PGD) was performed in order to identify the pattern of inheritance of the affected alleles by determining the presence of the mutation and related patterns of STR markers in the couple’s parents. The PGD protocol was performed according to the ESHRE PGD consortium best practice guidelines for amplification-based PGD (Harton ). In the first step, 4 ml of peripheral EDTA blood was taken from the couple and their parents. Then, the presence of the mutation was detected by PCR followed by Sanger sequencing. In addition, the pattern of three selected STR markers closely linked to the HSD3B2 gene was evaluated in the couples and their parents to enable linkage analysis and reveal the associated mutational inheritance. These markers were chosen based on their polymorphism and distance from the HSD3B2 gene. CODIS STRs and sex selection markers were also designed for further use. In the final step of PGD, semi-nested multiplex PCR was performed using the outer and inner primers listed in Table 1.
Table 1

Primer sequences for linked STR markers

Name Primer F1Primer F2                   Primer R                          
D1S185TGCCAGACCCCATAATGGCA TAATGGCATGAGCCAGTTCT TCAGGGTCCTCCTAAGAGAA
D1S534ACATACCATGAGACTTTAGCACA AGCACATAGCAGGCACTAGC CGATTGTGCCACTACACAGT
D1S514AATGCGTGGTCCCAAC CATTTTTAAACATCCGCACC GACTCAGACTTCCATCTGGACT
Primer sequences for linked STR markers The primer sequences of CODIS STRs used in the test are listed in Table 2. First-round multiplex PCR using the external primers was performed in a total volume of 50µl containing 1.5µl dNTP (10mM), 5µl 10X Buffer (MgCl2 50mmol, 10µl QS, 0.3µl Taq), 10µl Template, 0.2µl (20 pmol) of each primer and 22.5 µl DDW. PCR condition for the first round was 94°C for 3 min, 35 cycles at 94°C for 30'', 60°C for 30'', 72°C for 30'' and 72 °C for 7 min, carried out in an ABI 9700 machine. Direct mutation was analyzed by Sanger sequencing on an ABI 3130 sequencer. The PCR menu was as follows; total volume 20 µl in 5µl 5X Buffer, 1µl Big dye, 0.5µl Primer, 3µl PCR product and 12.5 µl DDW.
Table 2

Primer sequences for CODIS STRs

Name Forward primer Reverse primer
VWAGCCCTAGTGGATGATAAGAATAATCGGACAGATGATAAATACATAGG
THO1GTGATTCCCATTGGCCTGTTCATTCCTGTGGGCTGAAAAGCTC
Primer sequences for CODIS STRs The PCR program for the sequencing reaction was as follows: 96°C for 1 min, 25 cycles of 96°C 10s, 50°C 5s, 60°C 4 min, and finally incubation at 4°C for 7min. The PCR products of the first round were used as templates for the second round of PCR with a total volume of 20 µl, while the conditions for the second round were the same as in the first round. Finally, for direct mutation analysis the amplified inner products were electrophoresed in an automated genetic analyzer 3130 (Applied Biosystems). The results were analyzed on the Gene Mapper software (Applied Biosystems). For linkage analysis and sex selection, the amplified PCR products were electrophoresed on 12% acrylamide gel and stained with silver nitrate.

RESULTS

Three STR markers including; D1S185, D1S534, D1S514 and two CODIS STRs of VWA and THO1 were used. SRY and AMYLOGENIN were also used as sex selection markers. The couple had six day-3 embryos. The rate of ADO and contamination were 0%. The biopsy specimen from one of the embryos did not yield amplification, possibly due to the absence of cells. Additional tests confirmed wild type homozygosity in two (healthy), heterozygosity in two (carrier status), and mutant homozygosity (affected status) in one of the embryos (Fig. 2). One heterozygote male embryo was transferred to the mother's uterus and a singleton pregnancy was achieved. Prenatal diagnosis following amniocentesis on the 15th week of gestation confirmed the PGD results and the pregnancy resulted in the birth of a carrier boy.
Figure 2

Sanger sequencing results for the c.690 G>A mutation in the HSD3B2 gene for the transferred embryo

Sanger sequencing results for the c.690 G>A mutation in the HSD3B2 gene for the transferred embryo

DISCUSSION

Preimplantation genetic diagnosis has allowed the identification of various forms of genetic disorders from single embryo cells. PGD offers an authentic reproductive alternative to prenatal diagnosis (PND) and prevents the termination of pregnancies due to fetal affliction resulting from parental genetic disorders. PGD utilizes two strategies to find single gene abnormalities: direct and indirect mutation diagnosis. Although the direct approach is the gold standard in the identification of affected fetuses in PND, the possibility of losing one allele during PCR makes the indirect approach (linkage analysis) a good alternative to improve the validity of PGD results (Alberola ; Fiorentino ). For this reason, we used four polymorphic STR markers tied to the mutated gene to provide evidence of ADO (Fiorentino ; Gutiérrez-Mateo ). Steroid 3β-HSD defect is a rare cause of CAH, and is usually detected during the first few months of neonatal life. The diagnosis of this defect is based primarily on increased levels of Δ5 steroid hormones before and after an adrenocorticotropic hormone (ACTH) stimulation test subsequently confirmed by urinalysis (Moisan ). Prenatal genetic counseling is recommended for all families affected by CAH. In such an autosomal recessive disorder, one of 6 embryos will be affected when the two parents are carriers (Day ; Speiser ). We demonstrated a successful application of blastocyst biopsy, Sanger sequencing, and multiplex PCR for PGD of CAH, in conjunction with sex selection. In conclusion, multiplex semi-nested PCR was successfully used for the preimplantation genetic diagnosis of CAH, resulting in the birth of a disease-free healthy boy.
  13 in total

1.  New insight into the molecular basis of 3beta-hydroxysteroid dehydrogenase deficiency: identification of eight mutations in the HSD3B2 gene eleven patients from seven new families and comparison of the functional properties of twenty-five mutant enzymes.

Authors:  A M Moisan; M L Ricketts; V Tardy; M Desrochers; F Mébarki; J L Chaussain; S Cabrol; M C Raux-Demay; M G Forest; W G Sippell; M Peter; Y Morel; J Simard
Journal:  J Clin Endocrinol Metab       Date:  1999-12       Impact factor: 5.958

2.  Strategies and clinical outcome of 250 cycles of Preimplantation Genetic Diagnosis for single gene disorders.

Authors:  F Fiorentino; A Biricik; A Nuccitelli; R De Palma; S Kahraman; M Iacobelli; V Trengia; D Caserta; M A Bonu; A Borini; M Baldi
Journal:  Hum Reprod       Date:  2005-11-25       Impact factor: 6.918

3.  Disease expression and molecular genotype in congenital adrenal hyperplasia due to 21-hydroxylase deficiency.

Authors:  P W Speiser; J Dupont; D Zhu; J Serrat; M Buegeleisen; M T Tusie-Luna; M Lesser; M I New; P C White
Journal:  J Clin Invest       Date:  1992-08       Impact factor: 14.808

4.  Identification of non-amplifying CYP21 genes when using PCR-based diagnosis of 21-hydroxylase deficiency in congenital adrenal hyperplasia (CAH) affected pedigrees.

Authors:  D J Day; P W Speiser; E Schulze; M Bettendorf; J Fitness; F Barany; P C White
Journal:  Hum Mol Genet       Date:  1996-12       Impact factor: 6.150

Review 5.  Disorders of adrenal steroid biogenesis.

Authors:  A M Bongiovanni; W R Eberlein; A S Goldman; M New
Journal:  Recent Prog Horm Res       Date:  1967

6.  Congenital virilizing adrenal hyperplasia without acceleration of growth or bone maturation.

Authors:  T Aceto; M H MacGILLIVRAY; V J Caprano; R W Munschauer; S Raiti
Journal:  JAMA       Date:  1966-12-26       Impact factor: 56.272

7.  Polymerase chain reaction-based detection of chromosomal imbalances on embryos: the evolution of preimplantation genetic diagnosis for chromosomal translocations.

Authors:  Francesco Fiorentino; Georgia Kokkali; Anil Biricik; Dimitri Stavrou; Bahar Ismailoglu; Rosangela De Palma; Lucia Arizzi; Gary Harton; Mariateresa Sessa; Kostantinos Pantos
Journal:  Fertil Steril       Date:  2010-02-20       Impact factor: 7.329

8.  Preimplantation genetic diagnosis of P450 oxidoreductase deficiency and Huntington Disease using three different molecular approaches simultaneously.

Authors:  Trinitat M Alberola; Rosa Bautista-Llácer; Esther Fernández; Xavier Vendrell; Manuel Pérez-Alonso
Journal:  J Assist Reprod Genet       Date:  2009-07-21       Impact factor: 3.412

9.  Preimplantation genetic diagnosis of single-gene disorders: experience with more than 200 cycles conducted by a reference laboratory in the United States.

Authors:  Cristina Gutiérrez-Mateo; Jorge F Sánchez-García; Jill Fischer; Sophia Tormasi; Jacques Cohen; Santiago Munné; Dagan Wells
Journal:  Fertil Steril       Date:  2008-10-19       Impact factor: 7.329

Review 10.  Molecular basis of human 3 beta-hydroxysteroid dehydrogenase deficiency.

Authors:  J Simard; E Rheaume; F Mebarki; R Sanchez; M I New; Y Morel; F Labrie
Journal:  J Steroid Biochem Mol Biol       Date:  1995-06       Impact factor: 4.292

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.